糖心vlog

[Skip to Navigation]
Sign In

November 2024 - July 1883

Decade

Year

Issue

March 2, 2021, Vol 325, No. 9, Pages 805-898

This Week in JAMA

Audio Highlights

Abstract Full Text
free access online only has audio
JAMA. 2021;325(9):e2017821. doi:10.1001/jama.2020.17821
Original Investigation

Effect of Postreinduction Therapy Consolidation With Blinatumomab vs Chemotherapy on Disease-Free Survival in Children, Adolescents, and Young Adults With First Relapse of B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial

Abstract Full Text
free access
JAMA. 2021;325(9):833-842. doi:10.1001/jama.2021.0669

This randomized trial compares the effects of postreinduction therapy consolidation using blinatumomab, an antibody construct that links CD3+ T cells to CD19+ leukemia cells, vs chemotherapy on disease-free survival among children, adolescents, and young adults with first relapse of B-cell acute lymphoblastic leukemia (ALL).

Effect of Blinatumomab vs Chemotherapy on Event-Free Survival Among Children With High-risk First-Relapse B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial

Abstract Full Text
free access
JAMA. 2021;325(9):843-854. doi:10.1001/jama.2021.0987

This randomized trial compares the effects of blinatumomab, an antibody construct that links CD3+ T cells to CD19+ leukemia cells, vs consolidation chemotherapy as a third consolidation block before allogeneic hematopoietic stem cell transplant (HST) on event-free survival in children with high-risk first-relapse B-cell acute lymphoblastic leukemia (B-ALL).

Association of Intravenous Immunoglobulins Plus Methylprednisolone vs Immunoglobulins Alone With Course of Fever in Multisystem Inflammatory Syndrome in Children

Abstract Full Text
free access
JAMA. 2021;325(9):855-864. doi:10.1001/jama.2021.0694

This cohort study estimates the association of use of intravenous immunoglobulins (IVIG) plus methylprednisolone vs IVIG alone with treatment failure for multisystem inflammatory syndrome in children (MIS-C), defined as fever persistence at 2 days or fever recurrence within 7 days.

Research Letter

Change in Reported Adherence to Nonpharmaceutical Interventions During the COVID-19 Pandemic, April-November 2020

Abstract Full Text
free access
JAMA. 2021;325(9):883-885. doi:10.1001/jama.2021.0286

This study uses national survey data to describe overall and regional trends in adherence to protective behaviors (mask wearing, physical distancing, staying at home, others) among US adults during the COVID-19 pandemic from April to November 2020.

Association Between COVID-19 Lockdown Measures and Emergency Department Visits for Violence-Related Injuries in Cardiff, Wales

Abstract Full Text
free access
JAMA. 2021;325(9):885-887. doi:10.1001/jama.2020.25511

This study investigates emergency department visits for violence-related injuries occurring at home and outside the home in Cardiff, Wales, before and after COVID-19 lockdown measures were instituted in March 2020.

Viewpoint

Health Policy

Regulation of Health Care Prices: The Case for Backstop Price Caps in Commercial Health Care Markets

Abstract Full Text
JAMA. 2021;325(9):817-818. doi:10.1001/jama.2020.26821

This Viewpoint reviews evidence that higher hospital prices reflect greater market power more than higher-quality services and proposes that backstop price caps can mitigate harms from the most excessive prices without constraining or distorting competitive health care markets.

Health Policy

Paying for Prescription Drugs in the New Administration

Abstract Full Text
JAMA. 2021;325(9):819-820. doi:10.1001/jama.2021.0009

This Viewpoint discusses policies the Biden administration can enact to reduce costs, including benchmarking Medicare Part B drug payments to the lowest price paid in similar countries, preventing Part D plans from negotiating confidential rebates with manufacturers, and patent reform to promote generic drug use.

SARS-CoV-2 Vaccines and the Growing Threat of Viral Variants

Abstract Full Text
free access has multimedia has audio
JAMA. 2021;325(9):821-822. doi:10.1001/jama.2021.1114

This Viewpoint reviews circulating SARS-CoV-2 genetic variants and mechanisms of immunity by which they might escape coronavirus vaccine-induced protection and proposes 6 measures to address them, including enhanced variant isolation and testing procedures and continued adherence to mask-wearing and other established public health measures.

Data and Policy to Guide Opening Schools Safely to Limit the Spread of SARS-CoV-2 Infection

Abstract Full Text
free access
JAMA. 2021;325(9):823-824. doi:10.1001/jama.2021.0374

This Viewpoint from the CDC summarizes global data about SARS-CoV-2 outbreaks at K-12 schools and emphasizes implementation of community- and school-based policies shown to diminish spread of infection that would allow safer resumption of in-person education in the 2021/22 school year.

Funding of Pharmaceutical Innovation During and After the COVID-19 Pandemic

Abstract Full Text
free access has audio
JAMA. 2021;325(9):825-826. doi:10.1001/jama.2020.25384

This Viewpoint considers whether the shift away from private investment toward government funding of drug and vaccine development and commercialization during the coronavirus disease 2019 (COVID-19) pandemic is sustainable, arguing that the same or greater level of public investment will be necessary if drug prices are to remain affordable and if the US wants to maintain its global leadership position.

A Piece of My Mind

It鈥檚 Not Your Fault

Abstract Full Text
free access
JAMA. 2021;325(9):827-828. doi:10.1001/jama.2021.0255

In this narrative medicine essay an infectious diseases physician shares the sense of forgiveness she brings to anyone possibly involved in COVID-19 transmission, having learned as a child the healing power of family absolution after she witnessed the death of a cousin.

Editorial

Vaccine Distribution鈥擡quity Left Behind?

Abstract Full Text
free access has multimedia has audio
JAMA. 2021;325(9):829-830. doi:10.1001/jama.2021.1205

Blinatumomab for Treatment of Children With High-risk Relapsed B-Cell Acute Lymphoblastic Leukemia

Abstract Full Text
JAMA. 2021;325(9):830-832. doi:10.1001/jama.2021.1395
Review

Diagnosis and Treatment of Irritable Bowel Syndrome: A Review

Abstract Full Text
has audio
JAMA. 2021;325(9):865-877. doi:10.1001/jama.2020.22532

This narrative review summarizes the epidemiology, pathophysiology, diagnosis, management, and prognosis of irritable bowel syndrome.

JAMA Insights

Clinical Update

Diagnosis and Treatment of Nonscarring Hair Loss in Primary Care in 2021

Abstract Full Text
JAMA. 2021;325(9):878-879. doi:10.1001/jama.2020.19313

This JAMA Insights Clinical Update reviews the differential diagnosis, patterns, evaluation, and management of the most common causes of nonscarring hair loss, including male pattern balding, telogen effluvium, and alopecia areata.

From The Medical Letter on Drugs and Therapeutics

An EUA for Bamlanivimab鈥擜 Monoclonal Antibody for COVID-19

Abstract Full Text
free access
JAMA. 2021;325(9):880-881. doi:10.1001/jama.2020.24415

This Medical Letter review summarizes the evidence underlying the US Food and Drug Administration鈥檚 emergency use authorization of bamlanivimab, an investigational neutralizing IgG1 monoclonal antibody for treatment of COVID-19, including specification of high-risk patient groups eligible for the drug and its dosage and administration.

Medical News & Perspectives

Researchers Investigate What COVID-19 Does to the Heart

Abstract Full Text
free access has audio
JAMA. 2021;325(9):808-811. doi:10.1001/jama.2021.0107

This Medical News article discusses reports of myocardial injury and myocarditis among patients with COVID-19.

JAMA Live Highlights

Experts Discuss COVID-19鈥擵accine Doses, Virus Variants, and More

Abstract Full Text
free access has multimedia has audio
JAMA. 2021;325(9):812-813. doi:10.1001/jama.2021.1101

JAMA Live Highlights features comments from livestream interviews by 糖心vlog Editor in Chief Howard Bauchner, MD. His discussions with experts in clinical care, public health, and health policy focus on critical issues related to the coronavirus disease 2019 (COVID-19) pandemic. Comments have been edited for clarity.

News From the Food and Drug Administration

Monthly Injection Is Approved for Patients With HIV

Abstract Full Text
JAMA. 2021;325(9):816. doi:10.1001/jama.2021.1932

Rules Finalized for New Tobacco Product Approvals

Abstract Full Text
JAMA. 2021;325(9):816. doi:10.1001/jama.2021.1478

Import Alert on Hand Sanitizers From South of the Border

Abstract Full Text
JAMA. 2021;325(9):816. doi:10.1001/jama.2021.1934
The JAMA Forum

Trade-offs in Public Health Insurance Design

Abstract Full Text
free access
JAMA. 2021;325(9):814-815. doi:10.1001/jama.2021.0647
Poetry and Medicine

Reason for Everything

Abstract Full Text
free access
JAMA. 2021;325(9):892. doi:10.1001/jama.2020.23985
JAMA Revisited

鈥淎 General Practitioner,鈥 or All for Mercy鈥檚 Sake

Abstract Full Text
JAMA. 2021;325(9):893. doi:10.1001/jama.2020.17822
JAMA Patient Page

Necessity of 2 Doses of the Pfizer and Moderna COVID-19 Vaccines

Abstract Full Text
free access
JAMA. 2021;325(9):898. doi:10.1001/jama.2021.1375

This JAMA Patient Page describes how the new Pfizer and Moderna COVID-19 vaccines available in the US work and explains why 2 doses of these vaccines are needed to confer adequate immunity.

Comment & Response

The De-adoption of Low-Value Health Care

Abstract Full Text
JAMA. 2021;325(9):887-888. doi:10.1001/jama.2020.25515

The De-adoption of Low-Value Health Care鈥擱eply

Abstract Full Text
JAMA. 2021;325(9):888. doi:10.1001/jama.2020.25518

Antiretroviral Drug Recommendations for HIV Treatment and Prevention

Abstract Full Text
JAMA. 2021;325(9):888-889. doi:10.1001/jama.2020.25987

Antiretroviral Drug Recommendations for HIV Treatment and Prevention鈥擱eply

Abstract Full Text
JAMA. 2021;325(9):889-890. doi:10.1001/jama.2020.25990

Ticagrelor vs Clopidogrel for Patients With Acute Coronary Syndrome Undergoing Percutaneous Intervention

Abstract Full Text
JAMA. 2021;325(9):890. doi:10.1001/jama.2020.26020

Ticagrelor vs Clopidogrel for Patients With Acute Coronary Syndrome Undergoing Percutaneous Intervention鈥擱eply

Abstract Full Text
JAMA. 2021;325(9):890-891. doi:10.1001/jama.2020.26023
JAMA Masthead

JAMA

Abstract Full Text
free access
JAMA. 2021;325(9):805-806. doi:10.1001/jama.2020.17819
×